**Supplement 2**

Supplement to: **Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive care COVID-19 patients: The ReCOVery-SIRIO randomized trial**

Contents

[**Suppl. Table 1.** Association between biomarkers other than CRP and platelet count and mortality. 2](#_Toc112158052)

[**Suppl. Table 2.** Tested predictors for variable selection by cluster analysis. 3](#_Toc112158053)

[**Suppl. Table 3.** Adverse events. 4](#_Toc112158054)

[**Suppl. Figure 1.** CRP levels at 7,10 and 15 days stratified by presence (red) or absence (violet) of clinical improvement. 5](#_Toc112158055)

[**Suppl. Figure 2.** Cluster plot with 4 phenotypes. 6](#_Toc112158056)

## **Suppl. Table 1.** Association between biomarkers other than CRP and platelet count and mortality.

|  |  |  |  |
| --- | --- | --- | --- |
| Biomarker | Death (Yes) | Death (No) | P value |
| Plasma D-dimer (ng/ml) | 753 (500-946) | 665 (443-700) | 0.03 |
| WBC count day 7 (x103/mcL) | 8.13±4.81 | 8.91±3.50 | 0.48 |
| WBC count day 10 (x103/mcL) | 10.40±4.52 | 10.33±4.11 | 0.96 |
| WBC count day 15 (x103/mcL) | 11.96±4.67 | 10.46±4.49 | 0.47 |
| Lymphocyte count (x103/mcL) | 0.75 (0.46-1.27) | 1.02 (0.77-1.45) | 0.08 |
| Serum hs-cTroponin I day 7 (ng/ml) | 0.23 (0.006-0.30) | 0.007 (0.004-0.017) | 0.18 |
| Serum hs-cTroponin I day 10 (ng/ml) | 0.30(0.005-0.41) | 0.008 (0.004-0.014) | 0.36 |
| Serum hs-cTroponin I day 15 (ng/ml) | 0.15 (0.007-0.23) | 0.009 (0.005-0.018) | 0.16 |
| Serum MB-CK (IU/L) | 1.14 (0.50-2.12) | 1.79 (0.86-3.40) | 0.10 |
| Serum ALT (IU/L) | 27.15 (23-47.3) | 30 (20.70-52.6) | 0.88 |
| Values are median (IQR) or mean+SD. ALT=alanine aminotransferase, CK=creatine kinase, CRP=C-reactive protein, hs-c=high sensitivity-cardiac, MB, myocardium brain, WBC=white blood cell.  |

## **Suppl. Table 2.** Tested predictors for variable selection by cluster analysis.

|  |  |
| --- | --- |
|  |  |
| Peak serum C-reactive protein  | Blood lymphocyte count  |
| Nadir blood platelet count | Serum creatinine  |
| Serum ALT  | Serum AST  |
| Hs troponin I  | Plasma D-dimer  |
| Blood platelet count | Serum Creatine kinase   |
| Serum C-reactive protein | WBC count |
| PO2/FIO2 | Diabetes mellitus |
| Cancer  | Chronic obstructive pulmonary disease  |
| Age  | Sex |
| Cardiovascular disease  | Body mass index  |
| Serum MB-creatine kinase  | Aspirin  |
| Statins  | ACE-inhibitors  |
| Antidiabetic medications  | Diuretics  |
| Fever  | Dyspnoea  |
| Headache  | NEWS2 score  |
| Fatigue  | Systolic blood pressure  |
| Chest pain  | Diastolic blood pressure  |
| Pulse rate  | Hydroxychloroquine  |
| Ritonavir  | Lopinavir  |
| Azithromycin  | Remdesivir  |
| Convalescent plasma  | Supplemental oxygen  |
| Heparin  | ECMO  |
| Invasive mechanical ventilation  |  |

## **Suppl. Table 3.** Adverse events.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Amiodarone (n = 71) | Verapamil (n = 72) | Usual care(n = 72) | P |
| Ventricular tachiarrhythmia, n (%) | 0 (0) | 0 (0) | 0 (0) | 1 |
| Atrioventricular II or III degree block, n (%) | 0 (0) | 0 (0) | 1 (1) | 0.66 |
| Bradyarrhythmia (<40 bpm), n (%) | 1 (1) | 0 (0) | 3 (4) | 0.13 |
| Supraventricular tachiarrhythmia, n (%) | 4 (6) | 2 (3) | 0 (0) | 0.08 |
| Atrial fibrillation, n (%) | 0 (0) | 0 (0) | 1 (1) | 1 |
| Other serious event, n (%) | 1 (1) | 3 (4) | 1 (1) | 1 |
| Corrected QT interval at 15 days (ms), mean ±SD | 407.59**±**32.66 | 415.22**±**29.74 | 414.46**±** 32.80 | 0.90 |

## **Suppl. Figure 1.** CRP levels at 7,10 and 15 days stratified by presence (red) or absence (violet) of clinical improvement.



## **Suppl. Figure 2.** Cluster plot with 4 phenotypes.

